Naia Biotech applies CRISPR cell engineering to develop treatments for ultra-rare genetic diseases with small patient populations in Australia and New Zealand. Founded by researchers from Monash and CSIRO, the company leverages Australia's regulatory flexibility and world-class genomics research. Current pipeline includes two Phase 1 candidates targeting conditions with fewer than 500 patients globally.